Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel®
Industry development with potential relevance for veterinary professionals, companion animal care, and animal health stakeholders.
Digital tools are becoming increasingly important across veterinary medicine, from clinical workflows to client communication and practice operations.
According to the announcement, Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision. The development is relevant because it reflects how animal health companies, service providers, and technology platforms are responding to changing expectations in veterinary care.
What Was Announced
Kennewick, WA, June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a company pioneering Precision Radionuclide Therapy ™ (PRnT) with its innovative RadioGel ® technology, today announced the submission of its Early Feasibility IDE application to the FDA. This milestone represents a significant advancement in the Company’s regulatory pathway and builds directly on the substantial progress detailed in its February 10, 2026 update.
This targeted approach offers significant potential as a new treatment option for patients with difficult-to-treat tumors, including those with metastatic disease. It includes strengthened technical and manufacturing data confirming precise delivery and highly localized retention, additional clinical insights from the ongoing international human trial, updated preclinical evidence addressing prior Agency questions, and compelling real-world safety data from over 200 IsoPet ® veterinary patients across a wide range of tumor types with a favorable safety profile.
Why This Matters for Veterinary Professionals
For veterinary professionals, technology announcements matter when they affect efficiency, access to care, diagnostics, reimbursement, or the daily workflow of the clinic.
At the practice level, the most relevant question is whether the development can reduce administrative friction, improve access to information, or support more consistent communication between veterinary teams and clients.
Industry Perspective
The animal health industry continues to move toward more connected, data-driven services for veterinary practices and pet owners.
While individual announcements should be interpreted in the context of their source, they can help veterinary professionals monitor where investment, innovation, and market attention are moving across the animal health sector.
Original announcement: RadioGel ® technology, — https://www.globenewswire.com/news-release/2026/06/05/3307355/0/en/vivos-inc-otcqb-rdgl-submits-early-feasibility-investigational-device-exemption-ide-application-to-the-u-s-food-and-drug-administration-fda-for-radiogel-precision-radionuclide-ther.html
Comments
Related Articles
More news
Copyright © 2026 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment